Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_4
1
25%
Ph phase_2
2
50%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (50.0%)
Phase 41 (25.0%)
N/A1 (25.0%)

Trials by Status

unknown125%
recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingnot_applicable

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

NCT01962636
unknownphase_4

RituxiMab INDuction in Renal Transplantation

NCT01095172
completedphase_2

HSCT for High Risk Inherited Inborn Errors

NCT00383448
completedphase_2

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

NCT00186628

Clinical Trials (4)

Showing 4 of 4 trials
NCT01962636Not Applicable

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Recruiting
NCT01095172Phase 4

RituxiMab INDuction in Renal Transplantation

Unknown
NCT00383448Phase 2

HSCT for High Risk Inherited Inborn Errors

Completed
NCT00186628Phase 2

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4